FINNENCE ▪ THE WIRE FILE
THE WIRE · № 84050
News▲ Bullish
Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Expanding CHOICE arrangements grows Centene's employer-sponsored footprint across three states.
Incremental managed-care expansion, modest revenue contribution
CATALYST TO WATCH
2027 plan-year enrollment data
MAIN RISK
State program economics may disappoint
FULL DISPATCH
Expansion into Ohio and Oklahoma for plan year 2027 builds on early success offering employees CHOICE Arrangements in Indiana in 2026 ST. LOUIS, Oct. 16, 2026 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives,...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
CONTEXTHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Nabsys Launches RepX™ for Repeat Expansion Analysis Ahead of ASHG 20262026-10-16 12:00 UTC
Nabsys Launches RepX™ for Repeat Expansion Analysis Ahead of ASHG 20262026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Antihypertensive Drugs Market to Reach USD 30.92 Billion by 20352026-10-16 12:24 UTC
Antihypertensive Drugs Market to Reach USD 30.92 Billion by 20352026-10-16 12:24 UTC
→CORRELATIONshares Healthcare
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia2026-10-16 12:30 UTC
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia2026-10-16 12:30 UTC
→CORRELATIONshares Healthcare
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models2026-10-16 12:30 UTC
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models2026-10-16 12:30 UTC
→CORRELATIONshares Healthcare
Cyrano Therapeutics Announces Presentation of Positive Phase 2 FLAVOR Data Demonstrating Statistically Significant Improvement in Smell Function with CYR-064 in Patients with Post-Viral Smell Loss2026-10-16 12:30 UTC
Cyrano Therapeutics Announces Presentation of Positive Phase 2 FLAVOR Data Demonstrating Statistically Significant Improvement in Smell Function with CYR-064 in Patients with Post-Viral Smell Loss2026-10-16 12:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.